CompletedPhase 2

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

United States127 participantsStarted 2009-02

Plain-language summary

The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Clinical diagnosis of painful diabetic neuropathy. * non-fertile females Exclusion Criteria: * Other pain that may confound assessment of neuropathic pain. * Ongoing significant peripheral arterial diseases, skin ulcers, or amputation in the lower extremities. * History of psychotic disorders among first degree relatives.

What they're measuring

Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment

Timeframe: From baseline to day 28

Trial details

NCT IDNCT00857623

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-08

Results submitted2012-09-28

View on ClinicalTrials.gov More Pain trials